Traws Pharma (TRAW) Cash & Equivalents (2012 - 2026)

Traws Pharma (TRAW) has reported Cash & Equivalents for 15 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 80.34% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 80.34% YoY), while the FY2025 annual figure was $3.8 million, down 82.1% from the prior year.
• Cash & Equivalents slipped to $3.1 million in Q1 2026 per TRAW's latest filing, from $3.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $50.8 million in Q1 2022 and bottomed at $3.1 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $23.0 million across 5 years, with a median of $20.8 million in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 18.67% in 2025 and fell as far as 82.1% in 2025.
• Traws Pharma's Cash & Equivalents stood at $38.8 million in 2022, then sank by 46.28% to $20.8 million in 2023, then grew by 2.48% to $21.3 million in 2024, then plunged by 82.1% to $3.8 million in 2025, then declined by 17.98% to $3.1 million in 2026.
• Business Quant data shows TRAW's Cash & Equivalents at $3.1 million in Q1 2026, $3.8 million in Q4 2025, and $6.4 million in Q3 2025.